CINECA IRIS Institutional Research Information System

LONARDI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.273
AS - Asia 1.250
EU - Europa 746
SA - Sud America 318
AF - Africa 93
Totale 4.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.206
SG - Singapore 454
CN - Cina 311
BR - Brasile 257
IT - Italia 224
HK - Hong Kong 219
VN - Vietnam 109
SE - Svezia 105
DE - Germania 95
GB - Regno Unito 89
RU - Federazione Russa 43
CA - Canada 38
CI - Costa d'Avorio 36
BG - Bulgaria 35
FI - Finlandia 34
FR - Francia 32
IN - India 30
AR - Argentina 24
TR - Turchia 23
NL - Olanda 22
NG - Nigeria 18
JP - Giappone 17
MX - Messico 16
SN - Senegal 16
IQ - Iraq 14
AT - Austria 12
BD - Bangladesh 12
EC - Ecuador 11
PL - Polonia 11
CZ - Repubblica Ceca 8
EG - Egitto 8
ID - Indonesia 8
SA - Arabia Saudita 8
CO - Colombia 7
KR - Corea 7
ES - Italia 6
PE - Perù 6
PK - Pakistan 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
LT - Lituania 5
UA - Ucraina 5
NP - Nepal 4
VE - Venezuela 4
AZ - Azerbaigian 3
JO - Giordania 3
MY - Malesia 3
PA - Panama 3
PH - Filippine 3
PY - Paraguay 3
RO - Romania 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BO - Bolivia 2
DK - Danimarca 2
EE - Estonia 2
GR - Grecia 2
HN - Honduras 2
IR - Iran 2
KE - Kenya 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
CG - Congo 1
CH - Svizzera 1
CL - Cile 1
CR - Costa Rica 1
ET - Etiopia 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
LY - Libia 1
MN - Mongolia 1
MU - Mauritius 1
OM - Oman 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 4.680
Salva come PNG Salva come JPEG
Città #
Ashburn 272
Singapore 244
Hong Kong 216
Santa Clara 198
Woodbridge 144
Dallas 140
Fairfield 132
Chandler 128
Ann Arbor 116
Boardman 110
Houston 109
Shanghai 99
New York 71
Beijing 65
Seattle 56
Wilmington 49
Los Angeles 44
Cambridge 40
London 37
Abidjan 36
Council Bluffs 35
Sofia 35
Florence 32
Ho Chi Minh City 31
Princeton 29
Lawrence 27
São Paulo 26
Munich 24
Colorado Springs 20
Medford 20
Ogden 20
Frankfurt am Main 19
Pisa 19
Serra 18
Hanoi 17
Lagos 17
Dakar 16
Lancaster 16
Istanbul 14
Redondo Beach 14
Tokyo 14
Bremen 12
Buffalo 12
Milan 12
Ottawa 12
Rome 12
San Diego 12
Cascina 11
Helsinki 11
Turku 11
Dearborn 10
Des Moines 10
Düsseldorf 10
Hefei 10
Montreal 10
Baghdad 9
Chennai 9
Mexico City 9
Warsaw 9
Nuremberg 8
Poplar 7
Quanzhou 7
Seoul 7
Da Nang 6
Denver 6
Lauterbourg 6
Phoenix 6
San Jose 6
Toronto 6
Verona 6
Belo Horizonte 5
Brooklyn 5
Haiphong 5
Kent 5
Manchester 5
Redwood City 5
Sorocaba 5
Stockholm 5
Tashkent 5
Washington 5
Amsterdam 4
Ankara 4
Atlanta 4
Bogotá 4
Cairo 4
Chicago 4
Curitiba 4
Dong Ket 4
Florianópolis 4
Fuzhou 4
Guangzhou 4
Karachi 4
Nanjing 4
Norwalk 4
Orem 4
Qingdao 4
Salvador 4
Seacroft 4
Shenyang 4
Vienna 4
Totale 3.161
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 244
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 172
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 159
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 159
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 158
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 135
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 133
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 131
null 129
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 123
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 122
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 121
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 117
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 115
null 111
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 107
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 104
Epstein-Barr virus associated gastric dysplasia: a new rare entity? 103
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 100
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 98
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 96
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 91
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 90
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 90
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 90
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 89
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 87
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 84
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer 84
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 80
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial 80
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 78
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 74
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 73
Gastric cancer: Translating novels concepts into clinical practice 72
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 72
null 65
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 62
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 61
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 60
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 54
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 52
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer 49
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 43
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers 42
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 21
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 7
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 7
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 6
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 6
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 6
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 6
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 5
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study 1
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 1
Totale 4.787
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.477
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.477
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 0 17 4 14 16 12 16
2021/2022217 2 2 0 6 29 39 5 6 15 22 20 71
2022/2023455 35 80 42 31 52 38 7 24 97 1 40 8
2023/2024273 15 20 46 10 26 47 28 8 7 8 31 27
2024/20251.541 12 89 33 66 143 221 102 77 157 162 153 326
2025/20261.374 156 261 227 233 243 249 5 0 0 0 0 0
Totale 4.787